BJDX · XBRL financial data
Bluejay Diagnostics financial statements, every fiscal year
The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (BJDX's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | — | 249 | — | — | — |
| Cost of goods and services sold | — | 200 | — | — | — |
| Gross profit | — | 49 | — | — | — |
| Research and development | 1,148 | 4,152 | 5,715 | 3,472 | 3,046 |
| Selling, general and administrative | — | 451 | 283 | — | — |
| General and administrative | 1,792 | 4,763 | 4,313 | 3,690 | 3,907 |
| Total operating expenses | 3,230 | 9,367 | 10,311 | 7,170 | 6,953 |
| Operating income (loss) | (3,230) | (9,318) | (10,311) | (7,170) | (6,953) |
| Interest income | — | — | 165 | 146 | 98 |
| Interest expense | 6 | — | — | 823 | 1 |
| Other income (expense) | — | 168 | 192 | 129 | 8 |
| Net income (loss) | (3,488) | (9,297) | (9,954) | (7,718) | (6,848) |
| Earnings per share, basic USD per share | (0.41) | (0.46) | (9.08) | (114.19) | (15.25) |
| Earnings per share, diluted USD per share | (0.41) | (0.46) | (9.08) | (114.19) | (15.25) |
| Weighted average shares, basic thousands of shares | 8,522 | 20,164 | 1,097 | 183 | 449 |
| Weighted average shares, diluted thousands of shares | 8,522 | 20,164 | 1,097 | 183 | 449 |
- † Share count changed about 1/5 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (BJDX's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 19,048 | 10,115 | 2,209 | 4,302 | 5,165 |
| Prepaid and other current assets | 1,613 | 1,673 | 747 | 597 | 276 |
| Total current assets | 20,660 | 11,788 | 3,221 | 4,899 | 5,464 |
| Property and equipment, net | 337 | 1,232 | 1,286 | 1,513 | 1,534 |
| Right-of-use asset | — | 466 | 333 | 210 | 113 |
| Total assets | 21,019 | 13,521 | 4,869 | 6,657 | 7,119 |
| Accounts payable | 296 | 636 | 491 | 145 | 214 |
| Accrued liabilities | 339 | 836 | 1,117 | 552 | 805 |
| Total current liabilities | 637 | 1,640 | 1,771 | 810 | 1,119 |
| Lease liability, non-current | — | 324 | 190 | 109 | 20 |
| Total liabilities | 637 | 1,980 | 1,974 | 928 | 1,144 |
| Accumulated deficit | (7,695) | (16,997) | (26,951) | (34,669) | (41,517) |
| Total stockholders' equity | 20,382 | 11,541 | 2,895 | 5,729 | 5,975 |
| Total liabilities and equity | 21,019 | 13,521 | 4,869 | 6,657 | 7,119 |
| Common shares outstanding (cover page) thousands of shares | 20,151 | 20,459 | 2,688 | 554 | 972 |
- † Share count changed about 1/5 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (BJDX's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Net income (loss) | (3,488) | (9,297) | (9,954) | (7,718) | (6,848) |
| Stock-based compensation | 68 | 433 | 189 | 20 | 0 |
| Net cash from operating activities | (4,367) | (7,742) | (8,314) | (7,820) | (6,054) |
| Purchases of property and equipment | 24 | 1,199 | 704 | 307 | 174 |
| Net cash from investing activities | (24) | (1,199) | (704) | (307) | (174) |
| Proceeds from issuing common stock | — | — | 1,591 | 12,069 | 8,347 |
| Net cash from financing activities | 22,526 | 8 | 1,112 | 10,220 | 7,090 |
| Net change in cash | 18,135 | (8,933) | — | — | — |
- † Share count changed about 1/5 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Bluejay Diagnostics | 9,599 | not reported | (1,499)* | 4.5M | 6.4 quarters | 10-QJun 30, 2026 |
| Interpace Biosciences | 2,688 | 9,131 | 98* | 27.7M | — | 10-QJun 30, 2026 |
| Global Innovative Platforms | 244 | 51 | (134)* | 49.8M | 1.8 quarters | 10-QJun 30, 2026 |
| ENDRA Life Sciences | 1,740 | not reported | (928)* | 1.5M | 1.9 quarters | 10-QJun 30, 2026 |
| Stimcell Energetics | 6.9 | not reported | (109) | 21.1M | 0.1 quarters | 10-QAug 31, 2026 |
| LogicMark | 3,496 | 3,349 | 83* | 899,759 | — | 10-QJun 30, 2026 |
| INVO Fertility | 3,733 | 2,175 | (1,101)* | 2.5M | 3.4 quarters | 10-QJun 30, 2026 |
| Nu-Med Plus | 5.4 | 0 | 1.1* | 83.5M | — | 10-QJun 30, 2026 |
| STRATA Skin Sciences | 7,912 | 9,292* | (239)* | 5.9M | 33.1 quarters | 10-KDec 31, 2025 |
Not investment advice. Not affiliated with the U.S. SEC.